Teachers Advisors LLC decreased its stake in Dermira, Inc. (NASDAQ:DERM) by 34.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 174,093 shares of the biopharmaceutical company’s stock after selling 89,845 shares during the period. Teachers Advisors LLC owned about 0.49% of Dermira worth $5,938,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in the company. AXA raised its stake in Dermira by 10.9% in the first quarter. AXA now owns 212,254 shares of the biopharmaceutical company’s stock worth $7,240,000 after buying an additional 20,795 shares during the last quarter. Granite Investment Partners LLC bought a new stake in Dermira during the first quarter worth about $7,199,000. Bank of New York Mellon Corp raised its stake in Dermira by 34.5% in the first quarter. Bank of New York Mellon Corp now owns 199,852 shares of the biopharmaceutical company’s stock worth $6,817,000 after buying an additional 51,272 shares during the last quarter. Sei Investments Co. raised its stake in Dermira by 12.1% in the first quarter. Sei Investments Co. now owns 163,384 shares of the biopharmaceutical company’s stock worth $5,573,000 after buying an additional 17,600 shares during the last quarter. Finally, C WorldWide Group Holding A S raised its stake in Dermira by 83.9% in the first quarter. C WorldWide Group Holding A S now owns 82,746 shares of the biopharmaceutical company’s stock worth $2,822,000 after buying an additional 37,746 shares during the last quarter. 84.57% of the stock is currently owned by institutional investors and hedge funds.
Shares of Dermira, Inc. (NASDAQ:DERM) opened at 23.25 on Friday. Dermira, Inc. has a 12-month low of $21.35 and a 12-month high of $38.75. The firm’s market capitalization is $966.99 million. The stock’s 50 day moving average price is $28.06 and its 200-day moving average price is $30.67.
Dermira (NASDAQ:DERM) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by $0.04. Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. The firm had revenue of $1.07 million during the quarter, compared to analyst estimates of $1 million. On average, equities analysts expect that Dermira, Inc. will post ($4.17) EPS for the current year.
A number of equities research analysts recently issued reports on the company. BidaskClub raised Dermira from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Cantor Fitzgerald assumed coverage on Dermira in a research note on Thursday, June 22nd. They issued an “overweight” rating and a $45.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $46.00 target price on shares of Dermira in a research note on Tuesday, July 18th. Evercore ISI assumed coverage on Dermira in a report on Thursday, June 29th. They issued an “outperform” rating and a $48.00 price target for the company. Finally, Mizuho cut their price target on Dermira from $42.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, May 25th. Five analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. Dermira has a consensus rating of “Hold” and an average price target of $43.80.
In other Dermira news, CEO Thomas G. Wiggans sold 5,000 shares of the stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $29.06, for a total value of $145,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eugene A. Bauer sold 2,500 shares of the stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $30.00, for a total transaction of $75,000.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,812 shares of company stock valued at $482,231. Insiders own 13.30% of the company’s stock.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.